Cytheris to Present Interim Data from ECLIPSE II Hepatitis C Multicenter Study

Cytheris SA has announced that data from an interim analysis of its ECLIPSE II Hepatitis C Phase I/IIa multicenter study will be presented during a late breaker session at The Liver Meeting®, the 62nd annual meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco, November 4-8, 2011.
 
The ongoing study is evaluating treatment using the company’s investigative immune-modulator, recombinant human Interleukin-7 (CYT107), added to peginterferon and ribavirin (SOC), for four weeks, in genotype one and four treatment experienced patients defined as nonresponders to SOC.
 
The presentation details are as follows:

• Session: Poster session III, Monday, November 7

• Session title: HCV: clinical trials and therapeutic developments

• Session type: Late breaking poster session

• Location: Poster Hall

• Abstract number: LB-9

• Presentation time: 8:00 AM - 5:30 PM (presenters in attendance: 12:30 - 2:00 PM)

• Presentation title: Four weeks of IL-7 (CYT107) added to peginterferon and ribavirin (SOC) is safe, induces a broad immune response associated with HCV viral clearance in genotype one and four patients nonresponders to Peg-IFN and RBV.